Commit Biologics

Commit Biologics is a Danish biotech company founded in 2021 as a spin-out from Aarhus University, an academic institution with over three decades of complement research expertise. The company has raised €21.5 million in total funding, including a €16 million seed round in May 2024 led by Novo Holdings and Bioqube Ventures, followed by a €5.5 million extension in January 2025 from Korys. The company has also received a 5 million DKK Innobooster Grant from Innovation Fund Denmark and was initially incubated by the BioInnovation Institute in Denmark. The company's core technology platform, BiCE™ (Bispecific Complement Engaging), uses single domain antibodies that bind to complement protein C1q to direct the complement system in a highly targeted manner against specific cells. The platform is designed to overcome structural restraints that hinder conventional monoclonal antibodies from effectively engaging C1q, as well as address challenges posed by natural cell-bound complement inhibitors that are upregulated in cancer and low target densities. By combining single domain antibodies that engage C1q with an antibody that binds to a cellular target, BiCE™ technology can reportedly supercharge conventional monoclonal antibodies to activate the complement system more effectively than existing approaches. Commit is developing therapeutics for both cancer and autoimmune diseases using its modular platform, which can be applied across multiple tumor-associated antigens and immune cell targets. In November 2025, the company announced positive proof-of-concept results from a non-human primate study demonstrating rapid and deep depletion of B cells in blood and tissues following a single dose, with sustained B cell depletion for more than four weeks and a favorable safety profile with no adverse clinical observations and no cytokine release. Preclinical data has shown that second-generation BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies, including clinically approved T cell engagers and ADCC-enhanced antibodies. The company is currently in the preclinical stage, working towards drug candidate selection, with funding extending its runway into late 2026. Commit aims to disclose its first development candidate in 2026. The BiCE™ platform's modular, plug-and-play design allows it to integrate with existing antibody formats and can potentially be used in conjunction with other mechanisms of action, such as T-cell directed therapies or other targeted treatments. Commit's approach aims to address limitations of existing immunotherapies, including toxicities associated with antibody drug conjugates, T-cell engagers, and CAR-T therapies, as well as issues related to target density considerations and T-cell exhaustion. The founding team brings industrial experience from Alexion, Johnson & Johnson, Argenx, and Complement Pharma. In 2025, Mikkel Wandahl Pedersen, a seasoned R&D executive with over two decades of experience in immuno-oncology and autoimmune disease drug discovery, was appointed as Interim CEO, having previously served as CSO of Nykode Therapeutics and Symphogen.